Purchase this article with an account.
M.H. Oltmanns, F.A. Lattanzio, Jr., R.C. Allen, I.G. Castillo, P.B. Williams, A.H. Lichtman; Topical Win55 212–2 Reduces Intraocular Pressure in Ocular Hypertensive Rats . Invest. Ophthalmol. Vis. Sci. 2004;45(13):2093.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Introduction: Systemically administered cannabinoids lower intraocular pressure (IOP), but cause undesirable cardiovascular and CNS effects. This study examined the efficacy of topical Win55 212–2, a synthetic cannabinoid, in a model of ocular hypertension. Methods: 3 of 4 episcleral veins were ligated in Sprague–Dawley (n=20) and Long Evans (n=12) rats. After 4–6 wk, by Tonopen® or Goldmann tonometry IOP elevation was > 5 mm Hg. Blood pressure (BP), heart rate (HR), and IOP were measured at baseline, and 30, 60, 90, 120 min after topical instillation (20 uL) of Win55 212–2 (1, 0.5, 0.25, 0.125%) or timolol (0.5%). In other experiments, 50 ug/20 uL of SR141716, a CB1 (cannabinoid receptor) antagonist, was administered topically 30 min before Win55 212–2. Analysis for ocular irritation was performed by slit lamp examination (SLE) at baseline and 120 min.
This PDF is available to Subscribers Only